VistaGen Therapeutics, Inc.
VTGN · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 0.04 | -0.03 | 0.10 |
| FCF Yield | -55.08% | -24.76% | -199.30% | -18.52% |
| EV / EBITDA | -0.20 | 0.39 | -0.19 | -3.83 |
| Quality | ||||
| ROIC | -77.43% | -27.73% | -346.47% | -68.93% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.82 | 0.88 | 0.84 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -1.37% | – | – |
| Free Cash Flow Growth | -63.44% | 48.18% | -9.84% | -268.10% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 3.61 | 0.24 | 1.38 |
| Interest Coverage | 0.00 | 0.00 | -2,576.87 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1,290.69 | 903.79 |